Dr. Mark Steven McFarland, MD, MS

Dr. McFarland practices at Rochester General Hospital in Rochester, New York, part of Rochester Regional Health.

Dr. McFarland's NPI, 1750813051, was assigned on March 28, 2017. Dr. McFarland holds New York license 321965.

Dr. McFarland's primary practice is Rochester General Hospital, at 1425 Portland Avenue, Rochester, NY 14621 in Monroe County. The practice phone is (585) 922-4000.

Dr. McFarland's primary practice is Rochester General Hospital in Rochester, New York, part of Rochester Regional Health. Dr. McFarland is also affiliated with United Memorial Medical Center. The medical group on file is Rochester General Hospital. Dmand AI also links Dr. McFarland to 4 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McFarland practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. McFarland's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. McFarland's licenses on file in 2 states: New York and Connecticut.

CMS data shows 167 Medicare services from Dr. McFarland across 8 procedure codes in 2024, for 127 Medicare patients. Medicare paid $13,882 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 127 Medicare patients who saw Dr. McFarland in 2024. The largest group is 65 to 74, with 43 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 42% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McFarland's median patient age at 64, with 53% women.

In 2024, Dr. McFarland wrote 362 Medicare Part D claims for 106 patients. 93% of them were for generic drugs. CMS names the drug for 272 of them, across 4 drugs with 11 or more claims each, at $14,454 in total drug cost. In 2023, CMS named 75 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. McFarland for performance year 2024, reported through an alternative payment model (APM). Dr. McFarland accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. McFarland as offering telehealth. CMS counts 359 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. McFarland, more than 97% of the clinicians it reports for that procedure.

Dmand AI links 2 papers to Dr. McFarland, published from 2024 to 2025. Dr. McFarland's most frequent co-authors are Karin J. Dunnigan, MD, Jason P. Gutman, MD and Ali Jaan, MD.

CMS Open Payments shows 31 general payments to Dr. McFarland from 2 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. Boston Scientific Corporation paid the most, $888.